Abdelhak, A; Maceski, AM; Schädelin, S; Willemse, E; Oechtering, J; Zadic, A; Gomez, JFV; Melie-Garcia, L; Cagol, A; Galbusera, R; Subramaniam, S; Lorscheider, J; Galli, E; Müller, J; Fischer-Barnicol, B; Achtnichts, L; Findling, O; Lalive, P; Bridel, C; Uginet, M; Müller, S; Pot, C; Mathias, A; Du Pasquier, R; Salmen, A; Hoepner, R; Chan, A; Disanto, G; Zecca, C; DSouza, M; Hemkens, L; Janiaud, PMC; Yaldizli, Ö; Derfuss, T; Roth, P; Gobbi, C; Tackenberg, B; Brassat, D; Oksenberg, JR; Wiendl, H; Berger, K; Hermesdorf, M; Piehl, F; Conen, D; Buser, A; Kappos, L; Khalil, M; Granziera, C; Leppert, D; Benkert, P; Kuhle, J.
Treatment-associated changes in serum glial fibrillary acidic protein and neurofilament light chain levels and risk of disability progression independent of relapse activity in multiple sclerosis
MULT SCLER J. 2024; 30(3):1138-1140.-40th ECTRIMS Congress; SEP 18-20, 2024; Copenhagen, DENMARK.
[Oral Communication]
Web of Science